{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:25:10Z","timestamp":1778844310070,"version":"3.51.4"},"reference-count":56,"publisher":"Impact Journals, LLC","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,8,28]]},"DOI":"10.18632\/oncotarget.4230","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T04:49:54Z","timestamp":1442292594000},"page":"21159-21172","source":"Crossref","is-referenced-by-count":9,"title":["Bcl-2<i>high<\/i>mantle cell lymphoma cells are sensitized to acadesine with ABT-199"],"prefix":"10.18632","volume":"6","author":[{"given":"Arnau","family":"Montraveta","sequence":"first","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00edlvia","family":"Xargay-Torrent","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Rosich","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f2nica","family":"L\u00f3pez-Guerra","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Unitat d'Hematopatologia, Hospital Clinic, IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocabed","family":"Rold\u00e1n","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanina","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriong","family":"Lee-Verg\u00e9s","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merc\u00e8","family":"de Fr\u00edas","sequence":"additional","affiliation":[{"name":"Advancell-Advanced In Vitro Cell Technologies S.A., Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Camp\u00e0s","sequence":"additional","affiliation":[{"name":"Advancell-Advanced In Vitro Cell Technologies S.A., Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Campo","sequence":"additional","affiliation":[{"name":"Unitat d'Hematopatologia, Hospital Clinic, IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00ebl","family":"Rou\u00e9","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Unitat d'Hematopatologia, Hospital Clinic, IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2015,5,22]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Campo","year":"2012","journal-title":"J Clin Invest"},{"key":"2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: evolving management strategies","volume":"125","author":"Rule","year":"2015","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MOH.0000000000000057","article-title":"Do mantle cell lymphomas have an \u2018Achilles heel\u2019?","volume":"21","author":"Wiestner","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"4","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4161\/cc.10.13.16244","article-title":"LKB1\/AMPK\/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology","volume":"10","author":"Tamburini","year":"2011","journal-title":"Cell Cycle"},{"key":"5","doi-asserted-by":"crossref","first-page":"7365","DOI":"10.18632\/oncotarget.3629","article-title":"Targeting AMPK for cancer prevention and treatment","volume":"6","author":"Hua","year":"2015","journal-title":"Oncotarget"},{"key":"6","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1517\/14656566.9.12.2137","article-title":"Acadesine, an adenosine-regulating agent with the potential for widespread indications","volume":"9","author":"Kingwell","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/13543781003703694","article-title":"AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies","volume":"19","author":"Bontemps","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"8","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.18632\/oncotarget.413","article-title":"AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications","volume":"2","author":"Platanias","year":"2011","journal-title":"Oncotarget"},{"key":"9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.mito.2011.03.010","article-title":"Antiproliferative activity of levobupivacaine and aminoimidazole carboxamide ribonucleotide on human cancer cells of variable bioenergetic profile","volume":"12","author":"Rossignol","year":"2012","journal-title":"Mitochondrion"},{"key":"10","doi-asserted-by":"crossref","first-page":"39582","DOI":"10.1074\/jbc.M507443200","article-title":"5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferationandvia AMP-activated protein kinase","volume":"280","author":"Singh","year":"2005","journal-title":"J Biol Chem"},{"key":"11","doi-asserted-by":"crossref","first-page":"E435","DOI":"10.1073\/pnas.1311121111","article-title":"Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK","volume":"111","author":"Kendler","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1038\/onc.2012.339","article-title":"Aneuploid human colonic epithelial cells are sensitive to AICAR-induced growth inhibition through EGFR degradation","volume":"32","author":"Shay","year":"2013","journal-title":"Oncogene"},{"key":"13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.leu.2403593","article-title":"Acadesine induces apoptosis in B cells from mantle cell lymphoma and splenic marginal zone lymphoma","volume":"19","author":"Gil","year":"2005","journal-title":"Leukemia"},{"key":"14","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2002-07-2339","article-title":"Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes","volume":"101","author":"Gil","year":"2003","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1182\/blood-2010-05-283960","article-title":"AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells","volume":"116","author":"Pons","year":"2010","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.18632\/oncotarget.1455","article-title":"Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab inandmodels of mantle cell lymphoma","volume":"5","author":"Colomer","year":"2014","journal-title":"Oncotarget"},{"key":"17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-6-46","article-title":"Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy","volume":"6","author":"Barredo","year":"2007","journal-title":"Mol Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1750-2187-5-15","article-title":"AMPK-induced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia","volume":"5","author":"Barredo","year":"2010","journal-title":"J Mol Signal"},{"key":"19","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1182\/blood-2011-01-332783","article-title":"Antileukemic effects of AMPK activators on BCR-ABL-expressing cells","volume":"118","author":"Platanias","year":"2011","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00280-012-2033-5","article-title":"Acadesine for patients with relapsed\/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I\/II study","volume":"71","author":"Campas","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","article-title":"Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas","volume":"109","author":"Wheat","year":"2007","journal-title":"Blood"},{"key":"22","first-page":"482","article-title":"Regulation of VASP by phosphorylation: consequences for cell migration","volume":"7","author":"Storz","year":"2013","journal-title":"Cell Adh Migr"},{"key":"23","doi-asserted-by":"crossref","first-page":"H369","DOI":"10.1152\/ajpheart.00446.2012","article-title":"AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injury","volume":"304","author":"Tulis","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"24","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dolcetti","year":"2008","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1007\/s00018-008-8637-6","article-title":"Mcl-1 is a potential therapeutic target in multiple types of cancer","volume":"66","author":"Akgul","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.semcancer.2011.09.008","article-title":"New molecular targets in mantle cell lymphoma","volume":"21","author":"Wiestner","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Jin","year":"2013","journal-title":"Nat Med"},{"key":"28","doi-asserted-by":"crossref","first-page":"e97781","DOI":"10.1371\/journal.pone.0097781","article-title":"Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation","volume":"9","author":"Zheng","year":"2014","journal-title":"PLoS One"},{"key":"29","doi-asserted-by":"crossref","first-page":"e52852","DOI":"10.1371\/journal.pone.0052852","article-title":"Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastomaby decreasing angiogenesis and inducing apoptosis","volume":"8","author":"Vavvas","year":"2013","journal-title":"PLoS One"},{"key":"30","doi-asserted-by":"crossref","first-page":"e7889","DOI":"10.1371\/journal.pone.0007889","article-title":"Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death","volume":"4","author":"Auberger","year":"2009","journal-title":"PLoS One"},{"key":"31","doi-asserted-by":"crossref","first-page":"e93256","DOI":"10.1371\/journal.pone.0093256","article-title":"AMP-activated protein kinase suppresses theandproliferation of hepatocellular carcinoma","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"},{"key":"32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1158\/1055-9965.EPI-12-1014","article-title":"Association of AMP-activated protein kinase with risk and progression of non-Hodgkin lymphoma","volume":"22","author":"Zhu","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"33","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/cddis.2012.13","article-title":"Therapeutic metformin\/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy","volume":"3","author":"Zhao","year":"2012","journal-title":"Cell Death Dis"},{"key":"34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/iub.1213","article-title":"The multifaceted activities of AMPK in tumor progression\u2014why the \u201cone size fits all\u201d definition does not fit at all?","volume":"65","author":"Gantner","year":"2013","journal-title":"IUBMB Life"},{"key":"35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bbrc.2011.09.059","article-title":"Phosphorylation of VASP by AMPK alters actin binding and occurs at a novel site","volume":"414","author":"Hansen","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"36","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/ijc.26257","article-title":"Phosphorylation of vasodilator-stimulated phosphoprotein Ser239 suppresses filopodia and invadopodia in colon cancer","volume":"130","author":"Pitari","year":"2012","journal-title":"Int J Cancer"},{"key":"37","article-title":"Serine phosphorylation of vasodilator-stimulated phosphoprotein (VASP) regulates colon cancer cell survival and apoptosis","author":"Pitari","year":"2014","journal-title":"Life Sci"},{"key":"38","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/aps.2013.15","article-title":"Matrine inhibits the adhesion and migration of BCG823 gastric cancer cells by affecting the structure and function of the vasodilator-stimulated phosphoprotein (VASP)","volume":"34","author":"Yang","year":"2013","journal-title":"Acta Pharmacol Sin"},{"key":"39","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.bbamcr.2014.11.008","article-title":"Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells","volume":"1853","author":"Barcellos","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.semcancer.2011.09.006","article-title":"The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies","volume":"21","author":"Ford","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"41","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3324\/haematol.2013.088849","article-title":"The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt\/FoxO3a\/Bim axis in chronic lymphocytic leukemia cells","volume":"98","author":"Colomer","year":"2013","journal-title":"Haematologica"},{"key":"42","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.18632\/oncotarget.2253","article-title":"Dual PI3K\/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma","volume":"5","author":"Colomer","year":"2014","journal-title":"Oncotarget"},{"key":"43","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/leu.2011.364","article-title":"Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells","volume":"26","author":"Colomer","year":"2012","journal-title":"Leukemia"},{"key":"44","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1078-0432.CCR-12-1935","article-title":"Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma","volume":"19","author":"Colomer","year":"2013","journal-title":"Clin Cancer Res"},{"key":"45","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Spaargaren","year":"2013","journal-title":"Blood"},{"key":"46","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Radford","year":"2013","journal-title":"N Engl J Med"},{"key":"47","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/leu.2008.348","article-title":"Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma","volume":"23","author":"Rassidakis","year":"2009","journal-title":"Leukemia"},{"key":"48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd4505","article-title":"Targeting the translation machinery in cancer","volume":"14","author":"Topisirovic","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"49","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0804821105","article-title":"mTORC1 promotes survival through translational control of Mcl-1","volume":"105","author":"Housman","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"50","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.canlet.2012.11.013","article-title":"Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1","volume":"339","author":"Scholz","year":"2013","journal-title":"Cancer Lett"},{"key":"51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Adams","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"52","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/ijc.28206","article-title":"Concurrent inhibition of PI3K and mTORC1\/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma","volume":"133","author":"Scholz","year":"2013","journal-title":"Int J Cancer"},{"key":"53","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","article-title":"Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma","volume":"123","author":"Martinez-Climent","year":"2014","journal-title":"Blood"},{"key":"54","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.18632\/oncotarget.3275","article-title":"Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma","volume":"6","author":"Amiot","year":"2015","journal-title":"Oncotarget"},{"key":"55","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Almasan","year":"2015","journal-title":"Cell Death Dis"},{"key":"56","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/sj.onc.1207520","article-title":"Prospective strategies to enforce selectively cell death in cancer cells","volume":"23","author":"Blagosklonny","year":"2004","journal-title":"Oncogene"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T09:20:08Z","timestamp":1599556808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,22]]},"references-count":56,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2015,8,28]]}},"alternative-id":["4230","26110568"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.4230","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,22]]}}}